The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Anton Luger, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01695109
First received: September 19, 2012
Last updated: September 26, 2012
Last verified: September 2012
  Purpose

Clinical experience has confirmed the anorexic effect of Glucagon-like-peptide 1 (GLP-1) mimetics in comparison to DPP-4 inhibitors. A possible mechanism of this effect might be associated with changes in food choices, as suggested by animal studies. It has been shown that functional magnetic resonance imaging (fMRI) of the brain is a valuable tool in obesity research and can be used to study the response of several brain regions to the visual presentation of preferred in comparison to non preferred food items and to non food items The aim of this study is to search for possible effects of liraglutide in comparison to placebo on 1. food choices and 2. changes in brain function as evidenced by fMRI in healthy volunteers.

Findings of this study will help not only to get deeper insight into the mechanism of the anorexic effect of GLP-1 mimetics, but also into the regulation of food choices per se. In the future, it is planned to extend the results of this study in normal weight volunteers to obese diabetic subjects.


Condition Intervention Phase
Healthy Human Male Subjects
Drug: Liraglutide
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Food intake at an ad libitum buffet [ Time Frame: day 4 ] [ Designated as safety issue: No ]
    Food intake at the ad libitum buffet under liraglutide vs. placebo will be measured in details: total amount of calories, and where these calories derive from

  • fMRI activity in the brain [ Time Frame: day 4 ] [ Designated as safety issue: No ]
    fMRI activity in the brain during the high calorie/low calorie food items paradigm


Secondary Outcome Measures:
  • Changes in hunger and satiety scores on the visual analogue scales (VAS) over time as compared to baseline (measured in mm) during the study session [ Time Frame: timepoints -10, 90, 130 minutes ] [ Designated as safety issue: No ]

    Hunger-VAS forms include the question: How hungry do you feel? Subjects are required to mark their feeling of hunger in a scale of 0 to 100 mm.

    Satiety-VAS forms include the question: How satt do you feel? Subjects are required to mark their feeling of satiety in a scale of 0 to 100 mm.


  • Changes in Ghrelin, PYY, glucose and insulin concentrations during the study session [ Time Frame: timepoints -10, 90, 130 minutes ] [ Designated as safety issue: No ]
    Blood samples will be withdrawn from an intravenous cannula placed circa 10 minutes before the start of the study in the left antecubital vein. Samples will be immediately cooled on ice, centrifuged at 3000 rpm for 10 minutes and then stored at -20°C for the later measurement of insulin, ghrelin and PYY. All assays will be performed using commercial assay kits at the very end of the study with samples belonging to (both study days) one subject being measured within one kit.


Enrollment: 16
Study Start Date: November 2010
Study Completion Date: March 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
0.9% NaCl, 0.2 ml
Other Name: Isotonic saline
Active Comparator: Liraglutide Drug: Liraglutide
sc injections of 0.6 mg Liraglutide daily for three continuous days.
Other Name: Victoza

Detailed Description:

Design: The study is designed as a double blind, placebo controlled, randomized crossover intervention study with two arms (liraglutide first followed by placebo vs. placebo first followed by liraglutide) in 16 healthy male volunteers. fMRI results and food intake are compared between groups baseline vs. end of treatment period and placebo vs. liraglutide.

Intervention: A standard dose of 0.6 mg Liraglutide (oder placebo) will be used, and will be applied subcutaneously each morning for three subsequent days by the study personnel. Study sessions will be performed on the fourth day after placebo/liraglutide interventions.

Study sessions: On study days participants arrive at the trial centre at 8.00 am after a 12h fast. Participants are instructed to eat a light dinner around 8.00 pm the previous day and to spend around 8h resting during the night before the study days. Upon arrival, blood pressure and heart rate is measured and an iv line is started, from which a blood sample is taken from the antecubital vein for blood glucose, insulin and plasma hormone concentrations determination. The occurrence of nausea, vomiting, dizziness or any other adverse events (AE's) is reviewed together with the subject.

Instructions for the fMRI examination are reviewed together with the subject. The subject is advised to leave all ferromagnetic items behind, and baseline hunger/satiety visual analogue scales (VAS) are recorded. Then, the fMRI session with the food items paradigm (together with repeated recordings of hunger/satiety VAS) takes place. Afterwards, another blood sample and hunger/satiety VAS is taken and the subject is allowed to eat ad libitum from a buffet breakfast. Food intake is recorded in detail, including meal choices and calorie intake. After a final hunger/satiety VAS recording and another blood sample subjects are dismissed from the trial centre.

Outcome variables: Main outcome variables are fMRI activity in the brain during the high calorie/low calorie food items paradigm and food intake at the buffet liraglutide vs. placebo at the end of treatment. Secondary outcome parameters are hunger/satiety VAS ratings, total and active plasma ghrelin, peptide YY (PYY), glucose and insulin concentrations.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male healthy volunteers
  • Age 20-40
  • Non-smokers
  • Normal body weight (body mass index 19 -25 kg/m2)
  • Right handed
  • Signed informed consent
  • Willingness and ability to comply with the protocol

Exclusion Criteria:

  • Any history of or current drug abuse including alcohol consumption on a regular basis or binge drinking
  • Any history of or current psychiatric disease, including any eating disorder, as assessed by structured interview
  • Any history of dieting
  • Any condition interfering with fMRI measurements such as ferromagnetic implants or claustrophobia
  • Any evidence of relevant renal, liver, thyroid, cardiovascular, or respiratory illness at screening examination
  • Any acute illness necessitating medical treatment during the last 3 weeks before study entry, any permanent intake of medication
  • Any study participation in the last 3 months
  • HIV, hepatitis B or C positive
  • Any disease considered relevant for proper performance of the study or risks to the participant, at the discretion of the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01695109

Locations
Austria
Division of Endocrinology and Metabolism, Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Anton Luger, MD Medical University of Vienna
  More Information

No publications provided

Responsible Party: Anton Luger, Head of the Department of Endocrinology & Metabolism, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01695109     History of Changes
Other Study ID Numbers: 702/2008
Study First Received: September 19, 2012
Last Updated: September 26, 2012
Health Authority: Austria: "Österreichische Agentur für Gesundheit und Ernährungssicherheit"

Keywords provided by Medical University of Vienna:
GLP1
obesity
fMRI
ghrelin

Additional relevant MeSH terms:
Glucagon-Like Peptide 1
Liraglutide
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Incretins
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014